(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Clinical trial NCT05241873 · TERMINATED

Trial details

NCT number: NCT05241873
Sponsor: Blueprint Medicines Corporation
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Lung Neoplasm Malignant Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Disease Carcinoma, Bronchogenic Bronchial Neoplasms Adenocarcinoma Carcinoma Neoplasms by Histologic Type

Start date: 2022-03-04
Primary completion: 2024-07-31
Enrollment: 103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.